GlassScriptPhysician profile
Sarah Metz
NPI 1306505821
$6,835.07
in general payments reported to CMS, 2019-2025
22 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $159 · 2023: $975 · 2024: $4,332 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,082 · Food and Beverage: $2,245 · Travel and Lodging: $1,259 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,081.75 |
| Food and Beverage | $2,244.77 |
| Travel and Lodging | $1,259.28 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,621.03 | 2024 | |
| Janssen Biotech, INC. | $1,657.96 | 2023-2025 | Tecvayli, Rybrevant, Erleada |
| Incyte Corporation | $261.58 | 2023 | Jakafi |
| Gilead Sciences, INC. | $140.96 | 2023-2025 | Trodelvy |
| Cti Biopharma Corp. | $125.00 | 2023 | Vonjo |
| Sumitomo Pharma America, INC. | $122.35 | 2023 | Orgovyx |
| Eisai INC. | $121.55 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $119.24 | 2022-2023 | Onivyde, Somatuline Depot |
| Pfizer INC. | $118.92 | 2024 | |
| Legend Biotech USA INC. | $118.75 | 2025 | Carvykti |
| Myovant Sciences INC. | $81.49 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.19 | 2023 | |
| Novartis Pharmaceuticals Corporation | $45.41 | 2022-2025 | |
| Astellas Pharma US INC | $36.10 | 2024-2025 | Padcev, Xospata |
| Daiichi Sankyo INC. | $35.52 | 2023 | Enhertu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.86 | 2023-2025 | Lynparza, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $25.23 | 2025 | |
| Davol INC. | $22.56 | 2022 | |
| Tempus Ai, INC | $22.23 | 2024 | |
| Novocure INC. | $18.51 | 2025 | Optune Gio |
| Merck Sharp & Dohme LLC | $17.86 | 2025 | Keytruda, Welireg |
| Servier Pharmaceuticals LLC | $16.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Metz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.